About
Lou Tartaglia is the interim chief scientific officer of Editas Medicine and a partner at Third Rock Ventures. Lou has more than 20 years of scientific experience and therapeutic development leadership, and he is recognized as a thought leader in obesity and metabolic diseases. He has published more than 50 peer-reviewed scientific papers, including first authorship on a manuscript selected by Cell as one of the 15 most important papers published in 30 years. Prior to Third Rock, Lou was senior vice president and general manager of GeneLogic. Prior to GeneLogic, he was vice president of new ventures at Millennium Pharmaceuticals and also vice president of metabolic diseases, where he was responsible for the discovery and development of multiple therapeutic programs. Before joining Millennium, he worked at Genentech on the tumor necrosis factor receptors. Lou holds a Ph.D. in biochemistry from the University of California, Berkeley.
Position in the VCSift Database
- • 2 investors at Cure Ventures are tracked.
- • 41 investors hold the Managing Partner and Co-Founder role in VCSift. Lou Tartaglia is one of them.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
Contact Information
Find more investors like Lou
Search Investors